Seagen rolls out da­ta for Ad­cetris com­bi­na­tion to treat Hodgkin lym­phoma

Seagen has long held on to Ad­cetris as one of its top-sell­ing and ex­pand­ed prod­ucts, and the lat­est da­ta for the drug, used in com­bi­na­tion with oth­er ther­a­pies, show that the Wash­ing­ton state-based biotech is look­ing to con­tin­ue that strat­e­gy.

On Mon­day, Seagen un­veiled the re­sults from two parts of a Phase II tri­al eval­u­at­ing Ad­cetris in com­bi­na­tion with Bris­tol My­ers Squibb’s PD-1 in­hibitor Op­di­vo and “stan­dard chemother­a­py agents” for the front­line treat­ment of pa­tients with clas­si­cal Hodgkin lym­phoma. The oth­er parts of the tri­al eval­u­at­ed pa­tients with ad­vanced-stage dis­ease and ear­ly-stage dis­eases, with that part be­ing pre­sent­ed on a poster at the Amer­i­can So­ci­ety of Hema­tol­ogy’s an­nu­al meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER